临床试验/NCT01917578

NCT01917578Unknown3 期

Phase III Trail of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction

Shandong Cancer Hospital and Institute1 个研究点分布在 1 个国家目标入组 4 人开始时间: 2008年8月最近更新: 2013年8月6日

适应症

干预措施

试验速览

阶段: 3 期
发起方
入组人数: 4
试验地点: 1
主要终点: The shrinkage modes of breast tumor after NAC.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tumor excision in BCS can dramatically reduce IBTR.The main reseason of IBTR might be the uncertain shrinkage modes of the breast cancer after NAC.This clinical trial is firstly carried out to make clear the shrinkage modes of the primary tumor after 3 cycles and whole cycles of NAC,respectively,with whole-mount serial section(WMSS) and three-dimensional(3D) pathological reconstruction of the residual tumor.The second objective is to investigate the predictive value of 3D MRI reconstruction for the shrinkage modes of the primary tumor after NAC.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Diagnostic
盲法: None

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: Female
接受健康志愿者: 是

入选标准

•Female patients,locally advanced breast cancer,age ≥18 years.
•Histologically confirmed invasive adenocarcinoma of the breast.
•Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). (T1N0M0 lesions are excluded.)
•Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are acceptable. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. This will need to be re-evaluated after 3 cycles and prior to surgery.
•ECOG 0 or 2
•No distant metastasis, as documented by complete staging workup ≤6 weeks prior to initiation of study treatment.
•No previous treatment for breast cancer.
•Adequate hematologic function with:
•Absolute neutrophil count (ANC) >1500/μL. Platelets ≥100,000/μL. Hemoglobin ≥10 g/dL.
•Adequate hepatic function with:
•Serum bilirubin ≤ the institutional upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤2.5 x institutional ULN. Alanine aminotransferase (ALT) ≤2.5 x institutional ULN.
•Adequate renal function with serum creatinine ≤1.5 x ULN.
•Planned primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant chemotherapy

排除标准

•inflammatory breast cancer
•Pregnancy or breast-feeding.A negative serum pregnancy test within 7 days prior to first study treatment (Day 1, Cycle 1) for all women of childbearing potential is required. Patients of childbearing potential must agree to use a birth control method that is approved by their study physician while receiving study treatment and for 3 weeks after their last dose of study treatment. Patients must agree to not breast-feed while receiving study treatment.
•Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment.
•Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection.
•Concurrent treatment with any anti-cancer therapy other than those agents used in this study.
•Mental condition or psychiatric disorder that would prevent patient comprehension of the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.

研究组 & 干预措施

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Ultrasound (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: CNB (Procedure)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: BCS, Modified Radical Mastectomy (Procedure)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Pathologic Large Tissue Selected Table (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Leica TP1020 (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Pathologic Large Tissue Embedded Table (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Leica SM2000 R (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: HE Stain (Procedure)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: CX22 (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Epson V600 (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Three-Dimensional Reconstruction (Procedure)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: Mammography (Device)

Half Cycles Group

Experimental

Patients complete half of the whole cycles of neoadjuvant chemotherapy.

干预措施: TAC,TC,TA,CAF,CEF (Drug)